AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01438762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information, education and physiotherapy
Description: Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class.
Study NCT02785445 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dip.io Home Based Dipstick Analyzer
Description: First intervention (assigned to the All participants arm).
Study NCT02785445 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ACON U500 Mission® U500 Urine Analyzer
Description: Second intervention (assigned to the All participants arm).
Study NCT00774423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: 50 mg per day during 24 months
Study NCT00774423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: 50 mg per day during 24 months
Study NCT03602222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile web training LGBT mental health
Description: Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
Study NCT03602222 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person training LGBT mental health
Description: In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
Study NCT03889054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program
Description: The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts.
Study NCT01013740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine
Study NCT01013740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib
Study NCT01013740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib
Study NCT01013740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine
Study NCT01270698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-130
Description: IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
Study NCT03949712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Static Magnetic Field Stimulation (tSMS)
Description: tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
Study NCT03949712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Static Magnetic Field Stimulation (tSMS)
Description: Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
Study NCT00548847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
Study NCT00548847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-α-2b
Description: Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
Study NCT04933981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab for SARS-CoV-2
Description: in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
Study NCT02460536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification treatment (ABMT)
Description: Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
Study NCT02460536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure only +ABMT
Description: Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
Study NCT02460536 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention training only +ABMT
Description: Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
Study NCT02460536 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Identical discrimination task including a single non-emotional stimulus in each trial.
Study NCT01006889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
Study NCT03232034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Citrate
Description: 1000 mg calcium as calcium citrate
Study NCT03232034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Mineral Supplement
Description: Milk Minerals containing 1000 mg calcium
Study NCT03232034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Mineral Supplement
Description: Milk Minerals containing 1000 mg calcium
Study NCT03232034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate
Description: 50 g whey protein hydrolysate
Study NCT01642095 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03245177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 antibody
Study NCT03245177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60-66 Gy in 30-33 fractions, 2 Gy per fraction
Study NCT02138656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
Study NCT02138656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
Study NCT02138656 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
Study NCT02138656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard Care
Description: Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
Study NCT04582747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)
Description: Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively.
Study NCT01551069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine (Z0188)
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01551069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT02620956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nebulizing with heliox and oxygen
Description: Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
Study NCT02620956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nebulizing with heliox and oxygen
Description: Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
Study NCT01773876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis
Study NCT01773876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
Study NCT00296010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide 50 mg/day orally continuously for 16 weeks
Study NCT00296010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
Study NCT00296010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
Study NCT00296010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Study NCT00296010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00296010 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
Study NCT00296010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
Study NCT03569475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran extended-release oral capsules
Study NCT03569475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine oral capsules
Study NCT03569475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral capsules
Study NCT04311047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Description: Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
Study NCT03679897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine solution
Description: ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
Study NCT03679897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine solution
Description: ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
Study NCT04364685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on soft-sand
Description: The participants are required to walking on sand for 30 minutes. Walking is self-paced.
Study NCT04364685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking on Levelled Surface
Description: The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
Study NCT01062971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide-timolol-brimonidine
Description: Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
Study NCT03896074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered intravenously at 1200 mg every 3 weeks
Study NCT03896074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab intravenously at 15 mg/kg every 3 weeks
Study NCT01430208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resectoscopy
Description: hysteroscopy for myomas G0 and/or polyps
Study NCT02478385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care in a specially designed labour room
Description: Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
Study NCT02478385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive care in a specially designed labour room
Description: Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
Study NCT00195494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Study NCT00195494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2
Study NCT00195494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Study NCT03862261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated pediatric TB services
Description: pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~* Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~* Improvement of diagnosis capacities and their integration in all levels of care and all services.
Study NCT02870712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture of perineum
Description: suture of the tear to obtain hemostasis
Study NCT02870712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture of perineum
Description: suture of the tear to obtain hemostasis
Study NCT02870712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hemostatis by digital compression
Description: Digital compression of the tear to obtain hemostasis
Study NCT01395953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
Study NCT01395953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
Study NCT01400113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine Sublingual Tablet 10mg, single-dose
Study NCT01400113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sublingual Tablet, single-dose
Study NCT02934295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Determination of Anti-Rubella Antibody, E1
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01041781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01041781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01508936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Study NCT01508936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Study NCT03279679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: costoclavicular infraclavicular block
Description: Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
Study NCT03279679 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: paracoracoid infraclavicular block
Description: Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
Study NCT03279679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: All the nerve blocks will be performed under realtime ultrasound guidance
Study NCT03279679 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: All the nerve blocks will be performed under realtime ultrasound guidance
Study NCT03279679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% ropivacaine will be used for the brachial plexus block in both groups.